Evidence map›Paper›PMID 25499823›Full record

SynthesisEpidemiology and infection2015

Use of DALYs in economic analyses on interventions for infectious diseases: a systematic review.

A J J M Oostvogels, G A De Wit, B Jahn, A Cassini, E Colzani, C De Waure, M E E Kretzschmar, U Siebert, N Mühlberger, M-J J Mangen

Abstract readSystematic Review
In one paragraph

Synthesis in Epidemiology and infection, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cost-effectiveness thresholds: pros and cons.Bulletin of the World Health Organization · 2016
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

A J J M OostvogelsUniversity Medical Centre Utrecht (UMCU),Utrecht,The Netherlands.
G A De WitUniversity Medical Centre Utrecht (UMCU),Utrecht,The Netherlands.
B JahnInstitute of Public Health, Medical Decision Making and Health Technology Assessment,Department of Public Health and Health Technology Assessment,UMIT - University for Health Sciences,Medical Informatics and Technology,Hall i.T.,Austria.
A CassiniEuropean Centre for Disease Prevention and Control (ECDC),Stockholm,Sweden.
E ColzaniEuropean Centre for Disease Prevention and Control (ECDC),Stockholm,Sweden.
C De WaureInstitute of Public Health, Catholic University of the Sacred Heart,Rome,Italy.
M E E KretzschmarUniversity Medical Centre Utrecht (UMCU),Utrecht,The Netherlands.
U SiebertInstitute of Public Health, Medical Decision Making and Health Technology Assessment,Department of Public Health and Health Technology Assessment,UMIT - University for Health Sciences,Medical Informatics and Technology,Hall i.T.,Austria.
N MühlbergerInstitute of Public Health, Medical Decision Making and Health Technology Assessment,Department of Public Health and Health Technology Assessment,UMIT - University for Health Sciences,Medical Informatics and Technology,Hall i.T.,Austria.
M-J J MangenUniversity Medical Centre Utrecht (UMCU),Utrecht,The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A systematic literature review was performed on full economic evaluations of infectious disease interventions using disability-adjusted life years (DALY) as outcome measure. The search was limited to the period between 1994 and September 2011 and conducted in Medline, SciSearch and EMBASE databases. We included 154 studies, mostly targeting HIV/AIDS and malaria with most conducted for African countries (40%) and <10% in high-income countries. Third-payer perspective was applied in 29% of the studies, 25% used the societal perspective and 12% used both. Only 16% of the studies took indirect effects (i.e. herd immunity) of interventions into account. Intervention, direct healthcare and indirect non-healthcare costs were taken into account in respectively 100%, 81% and 36% of the studies. The majority of the studies followed the Global Burden of Disease method for DALY estimations, but most studies deviated from WHO cost-effectiveness guidelines. Better adherence to freely accessible guidelines will improve generalizability between full economic evaluations.

Indexed as

Guidelines as TopicQuality-Adjusted Life YearsCommunicable Disease ControlCost-Benefit AnalysisHumansWorld Health OrganizationCost-effectiveness analysiscostsdisability-adjusted life years (DALYs)economic evaluationinfectious diseasessystematic review

Identifiers

PMID25499823
PMCPMC4456769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.